Department of Biochemistry and Biophysics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA.
Department of Biochemistry and Biophysics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA; Biochemistry and Molecular Biophysics Graduate Group, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA.
Cell Rep. 2019 Aug 20;28(8):2080-2095.e6. doi: 10.1016/j.celrep.2019.07.069.
Hsp104 is an AAA+ protein disaggregase, which can be potentiated via diverse mutations in its autoregulatory middle domain (MD) to mitigate toxic misfolding of TDP-43, FUS, and α-synuclein implicated in fatal neurodegenerative disorders. Problematically, potentiated MD variants can exhibit off-target toxicity. Here, we mine disaggregase sequence space to safely enhance Hsp104 activity via single mutations in nucleotide-binding domain 1 (NBD1) or NBD2. Like MD variants, NBD variants counter TDP-43, FUS, and α-synuclein toxicity and exhibit elevated ATPase and disaggregase activity. Unlike MD variants, non-toxic NBD1 and NBD2 variants emerge that rescue TDP-43, FUS, and α-synuclein toxicity. Potentiating substitutions alter NBD1 residues that contact ATP, ATP-binding residues, or the MD. Mutating the NBD2 protomer interface can also safely ameliorate Hsp104. Thus, we disambiguate allosteric regulation of Hsp104 by several tunable structural contacts, which can be engineered to spawn enhanced therapeutic disaggregases with minimal off-target toxicity.
Hsp104 是一种 AAA+ 蛋白解聚酶,其自身调节的中间结构域(MD)中的多种突变可以增强其功能,从而减轻 TDP-43、FUS 和 α-突触核蛋白的毒性错误折叠,这些蛋白与致命的神经退行性疾病有关。有问题的是,增强的 MD 变体可能表现出非靶向毒性。在这里,我们通过在核苷酸结合域 1(NBD1)或 NBD2 中的单个突变来挖掘解聚酶序列空间,以安全地增强 Hsp104 的活性。与 MD 变体一样,NBD 变体可以抵抗 TDP-43、FUS 和 α-突触核蛋白的毒性,并表现出升高的 ATPase 和解聚酶活性。与 MD 变体不同的是,出现了非毒性的 NBD1 和 NBD2 变体,可以挽救 TDP-43、FUS 和 α-突触核蛋白的毒性。增强的取代改变了与 ATP、ATP 结合残基或 MD 接触的 NBD1 残基。改变 NBD2 单体界面也可以安全地改善 Hsp104。因此,我们通过几个可调谐的结构接触来阐明 Hsp104 的变构调节,这些接触可以被设计成产生具有最小非靶向毒性的增强型治疗性解聚酶。